Microvoltammetric electrodes were used to monitor dopamine released in the caudate nucleus of the rat after electrical stimulation of the medial forebrain bundle. The time resolution of the technique is sufficient to determine in vivo concentration changes on a time scale of seconds. Direct evidence identifying the substance released as dopamine was obtained both voltammetrically and pharmacologically. Administration of alpha-methyl-p-tyrosine terminates the release of dopamine, although tissue stores of dopamine are still present. Thus there appears to be a compartment for dopamine storage that is not available for immediate release. This compartment appears to be mobilized by amfonelic acid, since administration of this agent after alpha-methyl-p-tyrosine returns the concentration of dopamine released by electrical stimulation to 75 percent of the original amount.

Critical intracellular signals in normal and malignant cells are transmitted by the adaptor protein Grb2 by means of its Src homology 2 (SH2) domain, which binds to phosphotyrosyl (pTyr) residues generated by the activation of tyrosine kinases. To understand this important control point and to design inhibitors, previous investigations have focused on the molecular mechanisms by which the Grb2 SH2 domain selectively binds pTyr containing peptides. In the current study, we demonstrate that the Grb2 SH2 domain can also bind in a pTyr independent manner. Using phage display, an 11-amino acid cyclic peptide, G1, has been identified that binds to the Grb2 SH2 domain but not the src SH2 domain. Synthetic G1 peptide blocks Grb2 SH2 domain association (IC 50 10 -25 M) with a 9-amino acid pTyrcontaining peptide derived from the SHC protein (pTyr317). These data and amino acid substitution analysis indicate that G1 interacts in the phosphopeptide binding site. G1 peptide requires a YXN sequence similar to that found in natural pTyr-containing ligands, and phosphorylation of the tyrosine increases G1 inhibitory activity. G1 also requires an internal disulfide bond to maintain the active binding conformation. Since the G1 peptide does not contain pTyr, it defines a new type of SH2 domain binding motif that may advance the design of Grb2 antagonists.The binding characteristics of Src homology 2 (SH2) 1 domains determine their important role as regulators of intracellular signaling (1, 2). Signal flow requires a phosphotyrosyl (pTyr) residue in the target protein for binding by the SH2 domain (1, 3, 4). Interaction of SH2 domains with specific pTyr-containing proteins activates distinct signaling pathways. SH2 domains modulate the activities of c-src (5), alter the substrate specificity of c-abl proto-oncoproteins (6, 7), and transduce signals initiated at growth factor receptors (8) and cellular attachment systems (9). SH2 domains have been suggested as promising sites for therapeutic intervention (10). Consequently, there has been significant effort to understand the structural basis of SH2 domain binding to pTyr-containing targets (11-21).The Grb2 SH2 domain binds pTyr-containing motifs within several proteins including the adapter proteins SHC (22, 23), growth factor receptors such as members of the erbB family (23-27), morphology-determining proteins such as FAK (9), and cellular oncogenes such as 28). SH2 domain binding leads to activation of important downstream pathways by bringing the nucleotide exchange factor SOS1 to the membrane environment of p21 ras (29). Other pathways may be initiated through action of the Grb2 SH3 domain as well. These pathways are suggested by experiments showing that the SH3 domains of Grb2 can bind to other proteins including dynamin (30), Vav (31, 32), Cbl (33), and several as yet unidentified targets (34). A particularly important role for Grb2 in human cancer has been proposed for cells transformed by high levels of erbB2 (HER-2 or neu) expression (35,36). In these cells, the SH2 domain...

Select chemokine receptors act as coreceptors for HIV-1 entry into human cells and represent targets for antiviral therapy. In this report we describe a distamycin analogue, 2,2'-[4, 4'-[[aminocarbonyl]amino]bis[N,4'-di[pryrrole-2-carboxamide- 1, 1'-dimethyl]]-6,8-naphthalenedisulfonic acid]hexasodium salt (NSC 651016), that selectively inhibited chemokine binding to CCR5, CCR3, CCR1, and CXCR4, but not to CXCR2 or CCR2b, and blocked chemokine-induced calcium flux. Inhibition was not due to nonspecific charge interactions at the cell surface, but was based on a specific competition for the ligand receptor interaction sites since the inhibitory effect was specific for some but not all chemoattractant receptors. NSC 651016 inhibited in vitro replication of a wide range of HIV-1 isolates, as well as HIV-2 and SIV, and exhibited in vivo anti-HIV-1 activity in a murine model. In contrast, a distamycin analogue with similar structure and charge and the monomeric form of NSC 651016 demonstrated no inhibitory effects. These data demonstrate that molecules which interfere with HIV-1 entry into cells by targeting specific chemokine coreceptors can provide a viable approach to anti-HIV-1 therapy. NSC 651016 represents an attractive candidate for the chemotherapeutic treatment of HIV-1 infection and as a microbicide to prevent the sexual transmisssion of HIV-1. Moreover, NSC 651016 can serve as a template for medicinal chemical modifications leading to more effective antivirals.

In viva voltammetry has been used to measure the release of dopamine evoked by electrical stimulation of the medial forebrain bundle (MFB). Simultaneous measurements have been made with voltammetric-sensing electrodes ipsilateral to the stimulating electrode in the nucelus accumbens and the caudate nucleus of the anesthetized rat. During the stimulation, the species observed in both regions is voltammetrically identical to dopamine. Further evidence for the identity of dopamine is provided by anatomical, physiological, pharmacological, and postmortem data. Postmortem analysis of these brain regions after a single stimulation demonstrates that dopamine levels are unchanged, while dihydroxyphenylacetic acid (DOPAC) levels are increased in both regions. Systemic application of synthesis inhibitors results in a decrease in evoked release for each brain region. Amfonelic acid results in a restoration of stimulated release after synthesis inhibition. Evoked release is affected differently by pargyline in the two brain regions. The evoked release of dopamine is significantly elevated in the nucleus accumbens as a result of pargyline administration, but similar effects are not seen in the caudate nucleus. Tissue levels of dopamine are increased in both brain regions by pargyline, but the increase is significantly greater in the accumbens. Electrolytic lesions of the striatonigral pathway or systemic administration of picrotoxin eliminates the pargyline-induced difference in evoked release of dopamine. Amphetamine causes a reduction in stimulated release in the caudate nucleus with little effect on that observed in the nucleus accumbens. Administration of pargyline prior to amphetamine results in a diminution of release in both brain regions. Taken together, these data indicate that different factors affect regulation of the releasable pool of dopamine in the nucleus accumbens and caudate nucleus.Several major dopaminergic systems exist in the mammalian brain, including the nigrostriatal and mesolimbic systems. It is known that the mesolimbic system plays an important role in the regulation of normal brain function, and this role is distinct from that played by the nigrostriatal dopamine pathway (Mogenson and Yin, 1981;White and Wang, 1982). It has been shown by unit-recording techniques that these two regions respond in different manners to pharmacological stimuli thought to affect dopaminergic neurons (Rebec and Zimmerman, 1980; Reynolds et al., 1981). The behavioral responses elicited by electrical stimulation of these two pathways differ (van der Heyden, 1984). Lesions of the two regions also produce different behavioral responses (Kelly and Moore, 1976; Pycock and Marsden, 1978). Furthermore, anatomical differences have been shown at an ultrastructural level (Bouyer et al., 1984). A rec- Received June 10, 1985; revised Oct. 7, 1985; accepted Oct. 10, 1985. This work was supported by a grant from the National Science Foundation, Neurobiology Section.Correspondence should be addressed to R. M. Wigbtman, Department...

No abstract